solutions@vitroscan.com
solutions@vitroscan.com

News & Events

Meet VitroScan!

1 November 2025

In this video, Willemijn Vader explains how our ChemoPredict platform supports better treatment decisions.

Read more

VitroScan will be pitching at the Dutch Life Sciences Day investors forum

31 October 2025

Meet VitroScan at the Dutch Life Sciences Conference 2025 where Willemijn Vader will be pitching at the investors forum.

Read more

VitroScan awarded Kansen voor West grant to advance ex vivo tumor testing for next-generation immunotherapies

29 October 2025

VitroScan awarded 'Kansen voor West'-grant to advance ex vivo tumor testing for next-generation immunotherapies

Read more
More news

Info Sheets

Info Sheet ADC efficacy assessment

Info Sheet Bispecific antibody testing

Our latest scientific publication at a glance!

Koedoot et al., npj Precision Oncology, 2025

Scientific Posters

VitroScan at SITC 2025: Ex vivo micro-tumor testing identifies patient-specific anti-tumor immune responses to T cell engager ubamatamab

Download

VitroScan at ENA 2025: Bispecific antibody ubamatamab induces patient-specific anti-tumor immune responses in an ex vivo platform for ovarian cancer

Download

VitroScan at ESMO 2025: Chemo Sensitivity Score using an ex vivo 3D micro-tumor testing platform to predict clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer

Download

See more

 

Scientific Publications

Koedoot et al., npj Precision Oncology, 2025

Publication of our study showing that VitroScan's 3D ex vivo micro-tumor testing platform can accurately predict whether an ovarian cancer patient will respond to chemotherapy.

Read more

Connect with VitroScan

Contact us for more information on how our testing solutions can help you reduce risk and maximize success in your drug development process or for any other inquiries!

Contact

Home Insights